17 September 2026
In a landmark decision that promises to reshape the landscape of chronic disease management across the continent, Members of the European Parliament (MEPs) have officially adopted the Public Health Committee’s comprehensive report on cardiovascular diseases. The vote signals a decisive shift toward integrated, preventative healthcare, marking a major milestone in the European Union’s broader strategy to combat non-communicable diseases (NCDs).
By endorsing this report, the European Parliament has effectively reinforced the "Safe Hearts Plan"—a robust framework initiated by the European Commission to tackle the leading causes of mortality in Europe. For the European Respiratory Society (ERS) and other health advocates, the vote is not merely a bureaucratic achievement; it is a long-awaited recognition that the health of the heart and the health of the lungs are inextricably linked.
The Core Mandate: Integrating Care for Better Outcomes
At the heart of the newly adopted report is a push for a holistic approach to patient care. For decades, medical systems in Europe have operated in "silos," with cardiovascular specialists and respiratory experts often managing comorbid patients in isolation. The Parliament’s report seeks to dismantle these barriers, advocating for screening protocols and treatment pathways that treat the patient as a whole rather than a collection of distinct pathologies.
The report emphasizes that cardiovascular diseases (CVD) and respiratory conditions—specifically Chronic Obstructive Pulmonary Disease (COPD) and obstructive sleep apnoea—frequently coexist. By prioritizing early detection for both sets of conditions, the EU aims to significantly reduce the burden on healthcare systems and, more importantly, improve the quality of life for millions of European citizens living with chronic illness.
Chronology: The Path to Policy Transformation
The journey toward this legislative victory has been a multi-year effort involving intense collaboration between scientific bodies, patient advocacy groups, and policymakers.
- 2025: The Launch of the Safe Hearts Plan: The European Commission introduced the Safe Hearts Plan, a strategic initiative designed to address the surging prevalence of heart disease across Member States.
- Early 2026: Committee Deliberations: The European Parliament’s Public Health Committee began a series of intensive hearings, inviting clinical experts and stakeholders to provide evidence on the link between cardiac and pulmonary function.
- Mid-2026: Advocacy Intensification: The ERS and the European Lung Foundation ramped up their public awareness campaigns, most notably through "EU Screening Week," where they successfully lobbied for the inclusion of respiratory health checks within standard cardiac screening protocols.
- September 2026: The Plenary Vote: Following the committee’s positive recommendation, the full European Parliament convened to cast the final vote, resulting in the overwhelming adoption of the report.
Supporting Data: Why Integration is No Longer Optional
The urgency of this policy shift is underscored by sobering epidemiological data. Cardiovascular disease remains the leading cause of death in Europe, but the data suggests that mortality rates are heavily influenced by undiagnosed comorbidities.
The Respiratory-Cardiac Nexus
Research consistently shows that patients with COPD are at a significantly higher risk of cardiovascular events, including heart failure and myocardial infarction. The systemic inflammation caused by chronic lung conditions accelerates vascular damage, yet these patients are frequently overlooked in standard heart-health screenings.
Economic and Societal Burden
According to recent EU health assessments, NCDs account for nearly 80% of healthcare expenditure in the region. The current "reactive" model of care—where intervention occurs only after an acute cardiac or respiratory event—is both cost-prohibitive and clinically inefficient. By shifting the focus to early detection, the EU estimates that the Safe Hearts Plan could reduce hospitalizations for heart failure and respiratory exacerbations by as much as 15% over the next decade.
The Screening Gap
Current standardized health checks across many Member States often focus exclusively on blood pressure and cholesterol levels. The ERS has provided evidence suggesting that adding a simple lung function assessment—such as spirometry—to these check-ups would increase the detection of early-stage COPD by an estimated 25% in high-risk populations, providing a critical window for lifestyle interventions and pharmacological management.
Official Perspectives: Shaping the Future of Health Policy
The adoption of the report has drawn widespread praise from the scientific community. Raquel Duarte, ERS Director of Scientific Affairs to the EU, has been a vocal proponent of this integrated approach.
"This vote by the European Parliament marks an important step towards strengthening cardiovascular and respiratory health together," Duarte stated following the announcement. "The Safe Hearts Plan provides a valuable framework for addressing cardiovascular disease, and importantly its comorbidities and precursors across the entire health pathway—from prevention and early detection to treatment and rehabilitation."
Duarte further emphasized the necessity of addressing health inequalities: "We particularly welcome the strong focus on prevention, COPD, and on addressing the risk factors and inequalities that continue to shape cardiovascular health outcomes across Europe. The next step now is to ensure that the Safe Hearts Plan translates into clear and effective measures across the EU with the cooperation between European institutions, Member States, the scientific community, healthcare professionals, patients, and civil society."
Implications for the Future: A Paradigm Shift in Practice
The ripple effects of this vote are expected to be felt across the healthcare sectors of all 27 Member States. The implications are three-fold:
1. Clinical Practice Guidelines
The adoption of the report will likely lead to a revision of clinical guidelines. Physicians can expect new protocols that mandate integrated screening. For instance, a patient presenting with high blood pressure might automatically be screened for sleep apnoea or lung function, recognizing the potential for interconnected systemic issues.
2. Healthcare Infrastructure
Member States will be encouraged—and potentially incentivized through EU funding—to reform their primary care infrastructure. This includes training general practitioners in cross-disciplinary diagnostics and investing in the technology required for rapid, efficient screening in community settings.
3. Patient Empowerment and Advocacy
For the millions of patients living with chronic conditions, this policy shift represents a move away from the "revolving door" of hospitalizations. By focusing on early detection and comprehensive management, the EU is signaling a commitment to patient-centered care. Advocacy groups are already preparing to monitor the implementation of these measures, ensuring that the "Safe Hearts" framework does not remain a theoretical document but becomes a reality in clinics across Europe.
Conclusion: Turning Policy into Progress
As the European Union moves into the implementation phase of the Safe Hearts Plan, the focus must remain on the synergy between the scientific community and the political apparatus. The success of this initiative will ultimately depend on the willingness of Member States to translate these EU-wide recommendations into tangible, local policies.
The integration of respiratory and cardiovascular care is not just a clinical recommendation; it is a necessary evolution of 21st-century medicine. By recognizing the intricate links between our vital systems, the European Parliament has taken a bold step toward a healthier, more resilient Europe.
As we look toward the next steps, the message from the ERS and the Parliament is clear: when we treat the patient, we must treat the whole system. The path forward involves continued collaboration, rigorous data collection, and an unwavering commitment to the prevention of non-communicable diseases.
For further information on the ERS and the European Lung Foundation’s ongoing advocacy efforts regarding the integration of respiratory health into EU policy, please visit the official ERS advocacy page.
